Acetohydroxamic Acid

Summary

Acetohydroxamic Acid (CHEMBL734) is an approved small-molecule EC 3.5.1.5 (urease) inhibitor (ATC G04BX03); indicated across 6 conditions including urinary tract infection and urea cycle disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: G04BX03
• Indications: 6 conditions
• Clinical trials: 1
• Chemistry: 75.07 Da · C2H5NO2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL734
Name	Acetohydroxamic Acid
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	1990
ChEBI	CHEBI:27777
ATC	G04BX03
Molecular formula	C2H5NO2
Molecular weight	75.07
InChIKey	RRUDCFGSUDOHDG-UHFFFAOYSA-N

SMILES: CC(=O)NO

IUPAC name: N-hydroxyacetamide

ChEBI definition: A member of the class of acetohydroxamic acids that is acetamide in which one of the amino hydrogens has been replaced by a hydroxy group.

Pharmacological roles (ChEBI): EC 3.5.1.5 (urease) inhibitor.

Other ChEBI roles (chemical / environmental): algal metabolite.

Also known as: Acetohydroxamic acid, Acide acetohydroxamique, Acido acetohidroxamico, Lithostat, NSC-176136, N-Hydroxy-acetamide, N-hydroxyacetamide, acetohydroxamic acid, aceto hydroxamic acid, Aceto-hydroxamic acid, Acetohydroxamate, SID26747835

Patent coverage: 2,588 distinct patent families (7,079 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 7,078 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 7 (assay-derived). Sample: Lysine-specific demethylase 4E, Carbonic anhydrase 2, Prostaglandin G/H synthase 1, Bacterial urease, Urease subunit alpha/Urease subunit beta, Urease, Macrophage metalloelastase.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

6 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
urinary tract infection	4	MONDO:0100338	EFO:0003103
urea cycle disorder	1	MONDO:0004739	MONDO:0004739
ornithine carbamoyltransferase deficiency	1	MONDO:0010703	EFO:0007409
carbamoyl phosphate synthetase I deficiency disease	1	MONDO:0009376	EFO:0007193
argininosuccinic aciduria	1	MONDO:0008815	MONDO:0008815
citrullinemia	1	MONDO:0015991	MONDO:0015991

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07393438	PHASE2	NOT_YET_RECRUITING	Acetohydroxamic Acid Combined With a Short-Course Regimen for MDR-TB (AHA-PLUS)

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).